KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
FORT WASHINGTON, Pa., Feb. 25, 2016 -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter and full year 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 57209176 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORgt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 [email protected] Westwicke Partners John Woolford (443) 213-0506 [email protected] MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 [email protected]
